Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001172661-25-002072
Filing Date
2025-05-15
Accepted
2025-05-15 10:45:24
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 13035
  Complete submission text file 0001172661-25-002072.txt   14753
Mailing Address 701 LEE ROAD SUITE 103 WAYNE PA 19087
Business Address 701 LEE ROAD SUITE 103 WAYNE PA 19087 484-324-7933
Aclaris Therapeutics, Inc. (Subject) CIK: 0001557746 (see all company filings)

EIN.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-89137 | Film No.: 25949880
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 650 SOUTH EXETER STREET SUITE 1070 BALTIMORE MD 21202
Business Address 650 SOUTH EXETER STREET SUITE 1070 BALTIMORE MD 21202 4102200129
Rock Springs Capital Management LP (Filed by) CIK: 0001595725 (see all company filings)

EIN.: 800944416 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A